On January 30, 2026 Cycle Group Holdings Limited ("Cycle" or "Parent") reported that AT2B, Inc., a Delaware corporation ("Purchaser") and indirect wholly owned subsidiary of Cycle, has extended the expiration date of its tender offer to purchase all of the outstanding shares of common stock, par value $0.0001 per share of Applied Therapeutics, Inc., a Delaware corporation ("Applied") for (i) $0.088 per share, net to the seller in cash, without interest, plus (ii) one non-tradeable contingent value right per share.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The offer, which was previously scheduled to expire at one minute following 11:59 p.m., Eastern time, on January 29, 2026 is extended until one minute following 11:59 p.m., Eastern time, on February 2, 2026.

Equiniti Trust Company, LLC, the depositary for the offer, has advised Cycle that, as of 11:59 p.m., Eastern time, on January 29, 2026, approximately 75,895,437 shares (which include 2,429,370 shares subject to guaranteed delivery) have been validly tendered and not properly withdrawn pursuant to the offer, representing approximately 49.21% of the outstanding shares of Applied. Holders that have previously tendered their shares do not need to re-tender their shares or take any other action in response to this extension.

The offer is being made pursuant to the terms and conditions described in the offer to purchase, filed on December 29, 2025 (together with any amendments and supplements hereto), copies of which are attached to the tender offer statement on Schedule TO filed by Cycle and Purchaser with the US Securities and Exchange Commission, as amended.

The offer is conditioned upon the fulfilment of certain conditions described in Section 15—"Conditions to the Offer" of the offer to purchase, including, but not limited to, the tender of a majority of the then-outstanding shares of Applied’s common stock.

MacKenzie Partners, Inc. is acting as information agent for the offer. Requests for documents and questions regarding the offer may be directed to MacKenzie Partners, Inc by telephone, toll-free at 1-800-322-288. Bankers and Brokers may call at 212-929-5500.

(Press release, Cycle Pharmaceuticals, JAN 30, 2026, View Source [SID1234662375])

On January 30, 2026 Incyte (Nasdaq:INCY) reported that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Today’s positive CHMP opinion is an important step towards addressing the urgent need for new treatment options for patients in Europe with advanced SCAC, a disease which has seen limited innovation for decades," said Lee Heeson, Executive Vice President and Head of Incyte International. "If approved, Zynyz in combination with platinum-based chemotherapy has the potential to become a new standard-of-care for patients living with this rare and difficult-to-treat cancer."

The positive CHMP opinion was based on data from the Phase 3 POD1UM-303/InterAACT2 trial evaluating Zynyz in combination with (platinum-based chemotherapy) in adult patients with metastatic or inoperable locally recurrent SCAC not previously treated with systemic chemotherapy.5

Results from POD1UM-303/InterAACT2 (NCT04472429) published in The Lancet showed a statistically significant 37% reduction in the risk of progression or death (P=0.0006).4 Patients in the Zynyz and (platinum-based chemotherapy) combination group achieved a median progression-free survival (PFS) of 9.3 months compared to 7.4 months for patients in the placebo combination group.4 No new safety signals were identified. Serious adverse reactions occurred in 47% of patients receiving Zynyz in combination with chemotherapy.4 The most frequent serious adverse reactions (≥ 2% of patients) were sepsis, pulmonary embolism, diarrhoea and vomiting.4

SCAC is the most common type of anal cancer, accounting for approximately 85% of all anal cancer cases.6 Globally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men.

The CHMP opinion is now being reviewed by the European Commission, which has the authority to grant approval for all centrally authorized products in the EU.

About Squamous Cell Carcinoma of the Anal Canal (SCAC)
Worldwide, SCAC is the most common type of anal cancer, making up 85% of cases.6 It is a rare disease for which the incidence increases approximately 3% per year.7,8,9,10 About 90% of cases are associated with human papillomavirus (HPV) infection—the number one risk factor for anal cancer.10 HIV is an important amplifier of anal cancer, as people with HIV are 25 to 35 times more likely to develop it.11,12 Anal cancer shares many of the same symptoms as non-cancerous conditions, such as hemorrhoids—including pain, itching, a lump or mass and changes in bowel movements—and as a result can go undetected leading to the majority of patients presenting with locally advanced disease.13

About POD1UM
The POD1UM (PD1 Clinical Program in Multiple Malignancies) clinical trial program for retifanlimab includes POD1UM-303, POD1UM-202 and several other Phase 1, 2 and 3 studies for patients with solid tumors.

For more information about the study, please visit View Source

About Zynyz (retifanlimab)
Zynyz (retifanlimab) is a humanized monoclonal antibody targeting programmed death receptor-1 (PD-1), indicated in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC) in the U.S. and Japan and as a single agent for the treatment of adult patients with locally recurrent or metastatic SCAC with disease progression or intolerance to platinum-based chemotherapy in the U.S.

Zynyz is also indicated as monotherapy for the first-line treatment of adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC) in the U.S, EU, Canada, and Switzerland.

Zynyz is marketed by Incyte in the U.S. In 2017, Incyte entered into an exclusive collaboration and license agreement with MacroGenics, Inc. for global rights to retifanlimab.

Zynyz is a registered trademark of Incyte.

For more information, see the Zynyz SmPC.

(Press release, Incyte, JAN 30, 2026, View Source [SID1234662374])

On January 30, 2026 Kazia Therapeutics (NASDAQ: KZIA), an oncology-focused pharmaceutical company developing novel therapies for difficult-to-treat cancers, reported compelling preclinical and translational data supporting the development of NDL2, a potentially first-in-class protein degrader that is designed to selectively eliminate nuclear PD-L1, a previously unrecognized intracellular driver of immunotherapy resistance and metastatic progression that is not addressed by currently approved PD-1/PD-L1 antibodies. Across multiple preclinical models and patient-derived samples, NDL2 demonstrated reversal of immune exhaustion, suppression of metastatic biology, and enhanced anti-tumor activity, including in combination with anti-PD-1 therapy. By applying targeted protein degradation to one of the most clinically validated targets in oncology (PD-L1), Kazia aims to address a fundamental limitation of current immunotherapies while advancing a program aligned with growing strategic interest in protein degraders.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The data were generated by Professor Sudha Rao and her team at QIMR Berghofer and collectively support nuclear PD-L1 as a mechanistically distinct and therapeutically actionable driver of immune evasion, disease progression, and metastasis.

Key Highlights

Potentially first-in-class Nuclear PD-L1 degrader: Targets a newly discovered epigenetically regulated intracellular PD-L1 species driving immune evasion, metastasis, and resistance to checkpoint inhibitors.

Clear mechanistic differentiation: Unlike PD-1/PD-L1 antibodies that block extracellular signalling, NDL2 is designed to target nuclear PD-L1 proteins that are linked to aggressive and therapeutically resistant mesenchymal and stem-like cancer phenotypes.

In murine triple-negative breast cancer (TNBC) preclinical models, NDL2 reduced primary tumor volume by 49% as monotherapy and 73% in combination with anti-PD-1, with 50% reduction in lung metastases in the combination setting.

Favorable preclinical safety and pharmacokinetics (PK) profile: No observed toxicity, no hemolysis, preserved immune checkpoint function at the cell surface, and favorable plasma stability.

Nuclear PD-L1: A Newly Identified Driver of Resistance and Metastasis

Despite the transformative impact of immune checkpoint inhibitors, most solid tumors develop primary or acquired resistance, frequently accompanied by metastatic progression. Kazia’s collaborators identified nuclear PD-L1 as a transcriptionally active regulator that promotes:

Epithelial (benign) to Mesenchymal (aggressive) Transition (EMT)

Cancer stem-like phenotypes

Metastatic dissemination

Immune exhaustion and evasion

Nuclear PD-L1 was shown to be enriched in immunotherapy-resistant tumor cells, metastatic lesions, and circulating tumor cells (CTCs), and to regulate gene programs associated with invasion, survival, and immune suppression. Importantly, this intracellular PD-L1 pool is not addressed by existing PD-1/PD-L1 antibodies, representing a previously inaccessible resistance mechanism.

Robust Translational and Liquid Biopsy Evidence

Using an advanced epigenetic digital pathology and liquid biopsy platform, researchers demonstrated that:

Nuclear PD-L1 is selectively enriched in resistant and metastatic tumors, including TNBC, melanoma, non-small cell lung cancer (NSCLC), and colorectal cancer.

Distinct nuclear versus cytoplasmic PD-L1 post-translational modification states can be reliably quantified in circulating tumor cells.

Longitudinal liquid biopsy analysis showed that reductions in nuclear PD-L1 preceded radiographic tumor responses, supporting its potential utility as an early predictive biomarker of treatment benefit.

These findings support a precision-guided development strategy, integrating therapy and diagnostics from the outset.

Immune Reprogramming and Anti-Metastatic Activity

Spatial transcriptomic and proteomic profiling revealed that NDL2 treatment was able to drive a coordinated shift toward a less aggressive tumor state and a more active anti-tumor immune response in preclinical models, including:

Suppressed aggressive mesenchymal phenotype and metastasis-associated gene programs (including VIM, ZEB1, FN1);

Reduced oncogenic PI3K/AKT and MAPK signalling;

Increased intratumoral CD8+ cytotoxic T-cell infiltration and Granzyme B expression; and

Reduced markers of T-cell exhaustion, including TIM-3 and LAG-3.

In combination with anti-PD-1 therapy, these effects translated into meaningful reductions in metastatic burden in the preclinical models evaluated, supporting the potential of NDL2 to address one of the most significant limitations of current immunotherapies.

Strategic Validation: Protein Degradation as a High-Value Oncology Modality

Targeted protein degradation has emerged as a strategically important area of innovation in oncology, with large pharmaceutical companies increasingly prioritizing degrader-based approaches to address therapeutic resistance and intracellular targets not readily accessible through conventional modalities. Importantly, recent strategic acquisitions and collaborations in this space have been predominantly focused on research-stage and preclinical programs, reinforcing the industry’s willingness to invest meaningfully in degrader technologies well ahead of clinical proof-of-concept.

Against this backdrop, NDL2 uniquely combines an innovative approach with one of the most clinically validated targets in oncology. PD-L1 underpins multiple FDA-approved therapies across numerous tumor types and indications globally. By selectively degrading the nuclear, resistance-associated form of PD-L1, Kazia’s approach applies a novel and differentiated mechanism to a well-established biological pathway, positioning the program favorably for future strategic partnerships and long-term value creation.

Development Pathway and Outlook

NDL2 is a bicyclic peptide-based degrader, a modality that combines the selectivity of biologics with the tissue penetration, manufacturability, and pharmacokinetic advantages of small molecules. Future development of the program is supported by scalable synthetic manufacturing, favorable stability and PK characteristics, and absence of off-target nuclear effects observed to date.

Initial clinical development is expected to prioritize immunotherapy-refractory solid tumors where PD-L1 biology, metastatic progression, and resistance to immune checkpoint inhibitors are well established. Based on the underlying mechanism and preclinical data, these may include triple-negative breast cancer and melanoma, with potential expansion into larger PD-1/PD-L1-treated populations such as lung and colorectal cancers.

Kazia and its collaborators are advancing IND-enabling studies, with the objective of initiating first-in-human clinical trials in 2027, subject to regulatory review.

Kazia also plans to present elements of this dataset at an upcoming oncology-focused scientific meeting in the second quarter of 2026, where additional details on the underlying biology, translational findings, and therapeutic rationale for nuclear PD-L1 degradation are expected to be shared. Further program updates, including expanded preclinical and translational insights, are expected to be included in the Company’s next corporate presentation update scheduled for the first quarter 2026.

"The pharmaceutical industry is clearly signalling that targeted protein degradation represents a transformational opportunity in oncology," said Dr. John Friend, M.D., Chief Executive Officer of Kazia Therapeutics. "Recent high-profile acquisitions of preclinical protein degrader programs underscore the strategic value being placed on this modality. What differentiates NDL2 is that we are applying protein degradation to PD-L1 as one of the most clinically validated targets in cancer, while addressing a resistance mechanism not reached by existing therapies. Unlike programs focused on narrow biology, PD-L1 protein degraders offers multiple shots on goal across tumor types and treatment settings, which we believe creates a broad strategic partnering opportunity."

(Press release, Kazia Therapeutics, JAN 30, 2026, View Source [SID1234662373])

On January 30, 2026 Illumina, Inc. (NASDAQ: ILMN) reported that it has completed its acquisition of SomaLogic, a leader in data-driven proteomics technology. The highly complementary proteomics capabilities expand Illumina’s multiomics portfolio, strengthening customer access to proteomic insights at scale to help drive faster drug discovery and positively impact health care.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Welcoming the SomaLogic team to Illumina is an important milestone in executing the multiomics strategy we outlined in 2024," said Jacob Thaysen, chief executive officer of Illumina. "By combining SomaLogic’s highly differentiated proteomics technology with Illumina’s industry-leading innovation and global reach, we are strengthening our ability to deliver scalable insights across genomics and proteomics, helping customers unlock more from every sample in support of better outcomes for patients."

SomaLogic’s technologies provide deep insights into protein function, interactions, and modifications, helping to accelerate understanding of complex biology and human health. Customers will benefit from the combined power of SomaScan, Illumina Protein Prep, SomaSignal Tests, DRAGEN software, and Illumina Connected Multiomics to generate rich multiomic datasets at scale, with the flexibility to adopt the tools and workflows that best match their needs.

Illumina is building new, scalable growth businesses that complement and accelerate its high-throughput sequencing franchise. The SomaLogic acquisition ideally positions Illumina for growth in the expanding proteomics market by increasing customer access to SomaLogic’s technologies and service offerings, coupled with Illumina’s product innovation and global market reach.

Illumina remains an open, accessible, and enabling next-generation sequencing (NGS) platform, and will work closely with customers to provide continuity of products, services, and support as SomaLogic’s portfolio is integrated into Illumina’s product and solutions roadmap.

Illumina and SomaLogic have partnered in proteomics co-development since late 2021, when the companies entered into an agreement to bring the SomaScan Proteomics Assay onto Illumina’s high-throughput NGS platforms. The completed acquisition builds on this foundation, expanding Illumina’s presence in the large and growing proteomics market and advancing its leadership in multiomics. The company will continue to support SomaLogic customers and partnerships, including existing service providers using SomaLogic’s array-based readout.

Illumina acquired SomaLogic and other specified assets from Standard BioTools for $350 million, subject to customary adjustments, in cash paid at closing, plus up to $75 million in near-term performance-based milestones and performance-based royalties. The deal was funded with cash on hand, and Illumina will discuss the financial implications of the transaction in our upcoming earnings call scheduled for February 5, 2026.

(Press release, Illumina, JAN 30, 2026, View Source [SID1234662372])

On January 30, 2026 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) reported financial results for the fourth quarter and full year 2025 and provided a business update.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Regeneron performed well in 2025, with financial strength driven by our four blockbuster medicines and future growth supported by our exciting late-stage clinical portfolio," said Leonard S. Schleifer, M.D., Ph.D., Board co-Chair, President and Chief Executive Officer of Regeneron. "In the fourth quarter, we secured label expansions and new filler solutions for EYLEA HD, further enhancing its commercial potential. Dupixent received new approvals in Japan and Europe and is currently the most widely used innovative branded antibody medicine, with over 1.4 million active patients worldwide. Libtayo also secured additional approvals and continues to be the leading immunotherapy for non-melanoma skin cancers. Our current success is underscored by decades of investment in innovative science and technology, setting us up for exciting data read-outs and potential approvals in 2026 in a broad range of diseases."

Financial Highlights

($ in millions, except per share data) Q4 2025
Q4 2024
% Change FY 2025
FY 2024
% Change
Total revenues $ 3,884 $ 3,789 3 % $ 14,343 $ 14,202 1 %
GAAP net income $ 845 $ 918 (8 %) $ 4,505 $ 4,413 2 %
GAAP net income per share – diluted $ 7.86 $ 8.06 (2 %) $ 41.48 $ 38.34 8 %
Non-GAAP net income(a) $ 1,249 $ 1,390 (10 %) $ 4,888 $ 5,319 (8 %)
Non-GAAP net income per share – diluted(a) $ 11.44 $ 12.07 (5 %) $ 44.31 $ 45.62 (3 %)

"2025 was another strong year for Regeneron, marked by notable pipeline advances, remarkable commercial execution, and solid financial performance," said Christopher Fenimore, Executive Vice President, Finance and Chief Financial Officer of Regeneron. "As we look ahead to 2026, our focus remains on prioritizing internal investments, evaluating complementary business development opportunities, and enhancing shareholder returns through share repurchases and dividends, positioning the Company to deliver sustainable growth and long-term value to shareholders."

Business Highlights

Key Pipeline Progress
Regeneron has approximately 45 product candidates in clinical development, including a number of marketed products for which it is investigating additional indications. Updates from the clinical pipeline include:

Dupixent (dupilumab)

In November 2025, the European Commission (EC) approved Dupixent for the treatment of CSU in adults and adolescents aged 12 years and older who remain symptomatic despite antihistamine treatment. Dupixent is approved for CSU in certain adults and adolescents in several countries, including the United States and Japan. Additionally, regulatory applications are under review for CSU in children aged 2 to 11 years in the United States, European Union (EU), and Japan.
In December 2025, the Ministry of Health, Labour and Welfare (MHLW) in Japan approved Dupixent for the treatment of bronchial asthma in children aged 6 to 11 years with severe or refractory disease whose symptoms are inadequately controlled with existing therapy. This expands the previous approval of this indication in Japan for patients aged 12 years and older.
In November 2025, the Company and Sanofi announced positive results from the Phase 3 trial in adults and children aged 6 years and older with allergic fungal rhinosinusitis (AFRS). Additionally, the U.S. Food and Drug Administration (FDA) accepted for priority review the supplemental Biologics License Application (sBLA) for this indication, which has a target action date in February 2026.

EYLEA HD (aflibercept) 8 mg

In November 2025, the FDA approved EYLEA HD for the treatment of patients with RVO with up to every 8-week dosing after an initial monthly dosing period. The FDA also approved an every 4-week (monthly) dosing option across approved indications: wet age-related macular degeneration (wAMD), diabetic macular edema (DME), diabetic retinopathy (DR), and RVO.
In January 2026, the EC approved EYLEA 8 mg (known as EYLEA HD in the United States) for the treatment of RVO.
In December 2025, the FDA approved the addition of a new manufacturer to fill vials for EYLEA HD.
In December 2025, the Company submitted a regulatory application to the FDA to include a new manufacturer to fill pre-filled syringes for EYLEA HD. An FDA decision is expected in the second quarter of 2026.

Libtayo (cemiplimab)

In October and November of 2025, the FDA and EC, respectively, approved Libtayo as an adjuvant treatment for adults with CSCC at high risk of recurrence after surgery and radiation, making Libtayo the first and only immunotherapy approved in this setting. This expands Libtayo’s approved indications in CSCC beyond the metastatic or locally advanced setting. Additionally, in December 2025, a regulatory application was submitted in Japan for the adjuvant treatment of CSCC.

Other Programs

In December 2025, the Company submitted a BLA to the FDA for DB-OTO (an AAV-based gene therapy) for the treatment of profound genetic hearing loss in children due to variants of the otoferlin (OTOF) gene. An FDA decision is expected in the first half of 2026.
In December 2025, the Company submitted U.S. and EU regulatory applications for garetosmab (an Activin A antibody) in adults with fibrodysplasia ossificans progressiva (FOP).
A second Phase 3 study was initiated for REGN5713-5715, an investigational treatment for birch allergy.

Corporate Updates

In October 2025, Dupixent was recognized as the "Best Biotechnology Product" of 2025 by the Galien Foundation, which acknowledges extraordinary scientific innovations that improve the human condition.
In January 2026, the Company’s collaboration agreement with Tessera Therapeutics, Inc. to develop and commercialize TSRA-196 (Tessera’s investigational program for the treatment of alpha-1 antitrypsin deficiency (AATD)) became effective. Tessera will lead the initial first-in-human trial, while Regeneron will lead subsequent global development and commercialization.
In addition to the previously announced ongoing and planned domestic investments totaling more than $7 billion, the Company plans to invest approximately $2 billion to develop a state-of-the-art bulk manufacturing facility in Saratoga Springs, New York, expected to create 1,000 high-paying jobs and to significantly expand manufacturing capacity.

Select Upcoming 2026 Milestones

Programs Milestones
Ophthalmology - FDA decision for EYLEA HD pre-filled syringe (second quarter 2026)
- Report initial results from lead-in cohort of Phase 3 study for cemdisiran (C5 siRNA therapy) as monotherapy and in combination with pozelimab (C5 antibody) in geographic atrophy (second half 2026)
Immunology & Inflammation - EC decision on regulatory submission for Dupixent in bullous pemphigoid (first half 2026); FDA decision on sBLA for Dupixent in AFRS (February 2026)
- Initiate long-acting IL-13 antibody clinical program in atopic dermatitis (first half 2026)
- Initiate second Phase 3 study for REGN1908-1909 (Fel d 1 multi-antibody) in cat allergy (first half 2026)
Cardiovascular & Metabolic Diseases - Initiate Phase 3 program for olatorepatide (GLP-1/GIP receptor agonist) in obesity in patients with and without Type 2 diabetes (2026)
- Initiate clinical program for olatorepatide in combination with Praluent (alirocumab) (2026)
- Report additional data from Phase 2 study for semaglutide in combination with trevogrumab (myostatin antibody) with and without garetosmab (Activin A antibody) in obesity (2026)
Hematology - Initiate additional Phase 3 studies for Factor XI antibodies (REGN7508 and REGN9933) in anticoagulation (first half 2026)
- Report results from Phase 3 study for pozelimab (C5 antibody) in combination with cemdisiran (C5 siRNA therapy) in paroxysmal nocturnal hemoglobinuria (PNH) (fourth quarter 2026/first quarter 2027)
Oncology & Hematology-Oncology - Report results from Phase 3 study for fianlimab (LAG-3 antibody), in combination with Libtayo, versus pembrolizumab in first-line metastatic melanoma (first half 2026)
- Initiate additional Phase 3 studies for Lynozyfic (linvoseltamab) in multiple myeloma and precursor conditions (2026)
Neurology & Rare Diseases - FDA decision on BLA for DB-OTO (AAV-based gene therapy) in hearing deficit due to variants of the otoferlin gene (first half 2026)
- FDA decision on BLA and EC decision on MAA for garetosmab (Activin A antibody) in FOP (second half 2026)
- Submit New Drug Application (NDA) for cemdisiran (C5 siRNA therapy) in myasthenia gravis (first quarter 2026) and FDA decision on NDA (fourth quarter 2026/first quarter 2027)

Fourth Quarter and Full Year 2025 Financial Results

Revenues

($ in millions) Q4 2025
Q4 2024
% Change FY 2025
FY 2024
% Change
Net product sales:
EYLEA HD – U.S. $ 506 $ 305 66 % $ 1,637 $ 1,201 36 %
EYLEA – U.S. 577 1,190 (52 %) 2,748 4,767 (42 %)
Total EYLEA HD and EYLEA – U.S. 1,083 1,495 (28 %) 4,385 5,968 (27 %)
Libtayo – U.S. 285 251 14 % 945 787 20 %
Libtayo – ROW* 140 116 21 % 508 430 18 %
Total Libtayo – Global 425 367 16 % 1,453 1,217 19 %
Praluent – U.S. 73 63 16 % 262 242 8 %
Evkeeza- U.S. 48 38 26 % 162 126 29 %
Inmazeb- U.S. 37 40 (8 %) 37 76 (51 %)
Other products – Global 9 — ** 10 — **
Total net product sales 1,675 2,003 (16 %) 6,309 7,629 (17 %)

Collaboration revenue:
Sanofi 1,640 1,213 35 % 5,884 4,531 30 %
Bayer 319 377 (15 %) 1,422 1,499 (5 %)
Other 12 17 (29 %) 25 28 (11 %)
Other revenue 238 179 33 % 703 515 37 %
Total revenues $ 3,884 $ 3,789 3 % $ 14,343 $ 14,202 1 %

* Rest of world (ROW)
** Percentage not meaningful

Net product sales of EYLEA HD increased in the fourth quarter and full year 2025, compared to the same periods of 2024, due to higher sales volumes driven by increased demand, partly offset by a lower net selling price.

Net product sales of EYLEA in the fourth quarter and full year 2025, compared to the same periods of 2024, were negatively impacted by (i) lower sales volumes as a result of continued competitive pressures, loss in market share to compounded bevacizumab due to patient affordability constraints, and the continued transition of patients to EYLEA HD, and (ii) a lower net selling price.

In addition, as previously reported, EYLEA HD and EYLEA net product sales in the fourth quarter of 2025 were each favorably impacted by approximately $30 million due to higher wholesaler inventory levels at the end of the fourth quarter of 2025 compared to the end of the third quarter of 2025.

Sanofi collaboration revenue increased in the fourth quarter and full year 2025, compared to the same periods of 2024, due to an increase in the Company’s share of profits from the commercialization of antibodies, which were $1.486 billion and $1.043 billion in the fourth quarter of 2025 and 2024, respectively, and $5.242 billion and $3.924 billion for full year 2025 and 2024, respectively. The change in the Company’s share of profits from commercialization of antibodies was driven by higher profits primarily associated with an increase in Dupixent sales.

Refer to Table 4 for a summary of collaboration revenue.

Other revenue increased in the fourth quarter and full year 2025, compared to the same periods of 2024, primarily due to royalties earned on sales of Ilaris and share of profits from sales of ARCALYST, which were $179 million and $112 million in the aggregate for the fourth quarter of 2025 and 2024, respectively, and $506 million and $293 million for full year 2025 and 2024, respectively.

Operating Expenses

GAAP % Change
Non-GAAP(a) % Change
($ in millions) Q4 2025 Q4 2024 Q4 2025 Q4 2024
Research and development (R&D) $ 1,626 $ 1,412 15 % $ 1,331 $ 1,224 9 %
Acquired in-process research and development (IPR&D) $ 19 $ 14 36 % *
*
n/a
Selling, general, and administrative (SG&A) $ 775 $ 792 (2 %) $ 691 $ 681 1 %
Cost of goods sold (COGS) $ 319 $ 327 (2 %) $ 257 $ 271 (5 %)
Gross margin on net product sales(b) 81% 84% 85% 86%
Cost of collaboration and contract manufacturing (COCM)(c) $ 266 $ 239 11 % *
*
n/a
Other operating (income) expense, net $ — $ 16 (100 %) *
$ — **

GAAP % Change
Non-GAAP(a) % Change
FY 2025 FY 2024 FY 2025 FY 2024
Research and development $ 5,850 $ 5,132 14 % $ 5,150 $ 4,563 13 %
Acquired in-process research and development $ 124 $ 101 23 % * * n/a
Selling, general, and administrative $ 2,700 $ 2,954 (9 %) $ 2,311 $ 2,544 (9 %)
Cost of goods sold $ 1,141 $ 1,087 5 % $ 924 $ 898 3 %
Gross margin on net product sales(b) 82% 86% 85% 88%
Cost of collaboration and contract manufacturing(c) $ 960 $ 883 9 % * *
n/a
Other operating (income) expense, net $ (10 ) $ 53 ** * $ — **

* GAAP and non-GAAP amounts are equivalent as no non-GAAP adjustments have been recorded
** Percentage not meaningful

GAAP and non-GAAP R&D expenses increased for full year 2025, compared to the same period in the prior year, driven by the advancement of the Company’s late-stage clinical pipeline. GAAP R&D expenses for the fourth quarter and full year 2025 included $155 million related to a previously purchased FDA Rare Pediatric Disease Priority Review Voucher (PRV), which the Company decided in the fourth quarter of 2025 to utilize for a regulatory submission.
Acquired IPR&D expenses for full year 2025 included an $80 million up-front payment in connection with the Company’s license agreement with Hansoh Pharmaceuticals Group Company Limited. Acquired IPR&D expenses for full year 2024 included a $45 million development milestone in connection with the Company’s collaboration agreement with Sonoma Biotherapeutics, Inc.
GAAP and non-GAAP SG&A expenses decreased for full year 2025, compared to the same period in the prior year, primarily due to lower charitable contributions to Good Days, an independent non-profit patient assistance organization. GAAP and non-GAAP SG&A expenses in the fourth quarter 2025 included approximately $60 million for matching donations made to Good Days; in July 2025, the Company launched a matching program for donations made to Good Days and committed to matching donations quarterly through the end of 2025. The Company recently committed to matching donations for up to a total of $200 million during 2026.
GAAP and non-GAAP gross margin on net product sales decreased in the fourth quarter and full year 2025, compared to the same periods in the prior year, partly due to ongoing investments to support the Company’s manufacturing operations and higher inventory write-offs and reserves. In addition, GAAP gross margin on net product sales decreased due to higher amortization expense associated with the Company’s Libtayo intangible asset.

Other Financial Information

GAAP other income (expense), net included the recognition of net losses on marketable and other securities of $22 million in the fourth quarter of 2025, compared to net losses of $213 million in the fourth quarter of 2024. GAAP other income (expense), net included the recognition of net gains on marketable and other securities of $946 million for full year 2025, compared to net gains of $118 million for full year 2024.

In the fourth quarter and full year 2025, the Company’s GAAP effective tax rate (ETR) was 19.1% and 13.9%, respectively, compared to 4.2% and 7.7% in the fourth quarter and full year 2024, respectively. The GAAP ETR increased in the fourth quarter and full year 2025, compared to the same periods in the prior year, primarily due to lower tax benefits from less stock option exercises and the shortfall related to stock-based compensation. A shortfall occurs when the actual tax deduction a company recognizes from stock-based compensation is less than the deferred tax asset that was previously recorded for financial reporting purposes, resulting in the write-off of the deferred tax asset (and recognition of income tax expense). The GAAP ETR for the fourth quarter of 2025 was also negatively impacted by a lower benefit from income earned in foreign jurisdictions with tax rates lower than the U.S. federal statutory rate. The GAAP ETR for full year 2025 was positively impacted by the release of liabilities for uncertain tax positions recognized upon the settlement of an IRS audit. In the fourth quarter and full year 2025, the non-GAAP ETR was 17.1% and 12.6%, respectively, compared to 9.9% and 9.6% in the fourth quarter and full year 2024, respectively.

A reconciliation of the Company’s GAAP to non-GAAP results is included in Table 3 of this press release.

Capital Allocation

During the fourth quarter and full year 2025, the Company repurchased shares of its common stock and recorded the cost of the shares, or $671 million and $3.5 billion, respectively, as Treasury Stock. As of December 31, 2025, $1.5 billion remained available for share repurchases under the Company’s share repurchase programs.

In January 2026, the Company’s board of directors declared a cash dividend of $0.94 per share on the Company’s common stock and Class A stock, payable on March 5, 2026 to shareholders of record as of February 20, 2026.

2026 Financial Guidance*

The Company’s full year 2026 financial guidance consists of the following components:

2026 Guidance
GAAP R&D $6.450–$6.680 billion
Non-GAAP R&D(a) $5.900–$6.100 billion
GAAP SG&A $2.860–$3.040 billion
Non-GAAP SG&A(a) $2.500–$2.650 billion
GAAP gross margin on net product sales 79%–80%
Non-GAAP gross margin on net product sales(a) 83%–84%
COCM** $940 million–$1.020 billion
Capital expenditures** $1.100–$1.300 billion
GAAP effective tax rate 12%–14%
Non-GAAP effective tax rate(a) 13%–15%

* The Company’s 2026 financial guidance does not assume the completion of any business development transactions not completed as of the date of this press release
** GAAP and non-GAAP amounts are equivalent as no non-GAAP adjustments are expected to be recorded

A reconciliation of full year 2026 GAAP to non-GAAP financial guidance is included below:

Projected Range
($ in millions) Low High
GAAP R&D $ 6,450 $ 6,680
Stock-based compensation expense 550 580
Non-GAAP R&D(a) $ 5,900 $ 6,100

GAAP SG&A $ 2,860 $ 3,040
Stock-based compensation expense 360 390
Non-GAAP SG&A(a) $ 2,500 $ 2,650

GAAP gross margin on net product sales 79% 80%
Intangible asset amortization expense 3% 3%
Stock-based compensation expense 1% 1%
Non-GAAP gross margin on net product sales(a) 83% 84%

GAAP ETR 12% 14%
Income tax effect of GAAP to non-GAAP reconciling items 1% 1%
Non-GAAP ETR(a) 13% 15%

Conference Call Information

Regeneron will host a conference call and simultaneous webcast to discuss its fourth quarter and full year 2025 financial and operating results on Friday, January 30, 2026, at 8:30 AM Eastern Time. Participants may access the conference call live via webcast, or register in advance and participate via telephone, on the "Investors and Media" page of Regeneron’s website at www.regeneron.com. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the conference call and webcast will be archived on the Company’s website for at least 30 days.

(Press release, Regeneron, JAN 30, 2026, View Source [SID1234662371])